- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | Earnings Call Transkript: ImmuCell-Aktie legt nach gemischten Q4-Zahlen 2025 zu | 2 | Investing.com Deutsch | ||
| 08.01. | ImmuCell meldet Q4-Umsatz von 7,6 Mio. US-Dollar und richtet Fokus neu auf First Defense | 1 | Investing.com Deutsch | ||
| IMMUCELL Aktie jetzt für 0€ handeln | |||||
| 08.01. | ImmuCell reports preliminary Q4 results | 1 | Seeking Alpha | ||
| 08.01. | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 | 593 | GlobeNewswire (Europe) | PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that... ► Artikel lesen | |
| 08.01. | IMMUCELL CORP /DE/ - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | - | SEC Filings | ||
| 26.12.25 | ImmuCell Puts Re-Tain On Pause After FDA Letter | 3 | Benzinga.com | ||
| 24.12.25 | ImmuCell shifts focus to First Defense after FDA setback for Re-Tain | 1 | Investing.com | ||
| 24.12.25 | ImmuCell: Strategiewechsel nach FDA-Rückschlag für Re-Tain | 1 | Investing.com Deutsch | ||
| 24.12.25 | ImmuCell Corporation: ImmuCell Announces Strategic Focus on First Defense After Receiving an FDA Incomplete Letter for Re-Tain | 1.035 | GlobeNewswire (Europe) | PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health... ► Artikel lesen | |
| 14.11.25 | ImmuCell signals operational excellence and targets $30M annual production capacity amid management transition | 2 | Seeking Alpha | ||
| 14.11.25 | ImmuCell Q3 2025 slides: Improved margins despite revenue dip, Re-Tain awaits FDA | 2 | Investing.com | ||
| 14.11.25 | ImmuCell: Margen steigen trotz Umsatzrückgang - Warten auf FDA-Zulassung für Re-Tain | 11 | Investing.com Deutsch | ||
| 04.11.25 | ImmuCell appoints Olivier te Boekhorst as new CEO | 1 | Investing.com | ||
| 07.10.25 | ImmuCell announces preliminary sales results for Q3 | 1 | Seeking Alpha | ||
| 07.10.25 | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 | 120 | GlobeNewswire (Europe) | PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 07.10.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09.25 | ImmuCell names Olivier te Boekhorst as new president and CEO | 1 | Investing.com | ||
| 29.09.25 | ImmuCell Corporation: ImmuCell Announces Selection of its Next President and CEO | 156 | GlobeNewswire (Europe) | PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,218 | -0,80 % | Evotec Aktie: Comebacktitel für 2026? | Aktionäre von Evotec müssen viel Geduld aufbringen. Seit Monaten scheitern immer wieder die Versuche der Biotech-Aktie, stabil über die 200-Tage-Linie zu springen. An oder knapp oberhalb des viel beachteten... ► Artikel lesen | |
| BB BIOTECH | 50,60 | -0,20 % | BB Biotech und HBM Healthcare: Erfreulicher Zahlenreigen | ||
| QIAGEN | 44,620 | +0,64 % | Adidas schmiert ab, Qiagen zieht an: DAX-Ausblick | Der DAX hat eine volatile Woche hinter sich. Unter dem Strich büßte das größte deutsche Börsenbarometer knapp 400 Punkte ein und schloss -1,57% tiefer mit 24.900 Punkten. Die höchsten Verluste gab es... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| ILLUMINA | 122,04 | -0,08 % | Illumina, Inc.: Illumina completes acquisition of SomaLogic from Standard BioTools Inc. | Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 626,80 | +0,16 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q4 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) announced a profit for fourth quarter that Drops, from the same period last yearThe company's earnings totaled $844.6 million, or... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,370 | 0,00 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OCUGEN | 1,218 | -0,69 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,550 | +1,31 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 5,586 | +0,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,360 | -0,73 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen |
Das Unternehmen IMMUCELL CORPORATION kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,920 Euro und damit -4,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUCELL CORPORATION finden Sie auf Wallstreet Online.